



# European Colorectal Congress

29 November – 2 December 2020, St.Gallen, Switzerland

## MASTERCLASS

Handling large rectal adenoma and malignant polyps

Do and don't in taTME surgery – a decade of experience explained

Prehabilitation, patient blood management, frailty index – welcome addition or resource wasting?

What your pathologist can do for you: from standard margins recommendations to molecular pathology/liquid biopsies and the microbiome

All techniques to avoid staple line intersections in colorectal surgery

Myths and facts about oral antibiotics, bowel preparation, and timing of iv antibiotics to reduce surgical site infection

Selective use of neoadjuvant and adjuvant radiotherapy for rectal cancer

Management of colorectal GIST – all you should know from diagnosis to handling recurrences

Management of pelvic sepsis after colorectal / coloanal anastomosis and oncological outcomes of the GRECCAR 5 trial

Best practices in colostomy construction and repair of parastomal hernia

The EBSQ Coloproctology Examination

## COURSE OF PROCTOLOGY SCIENTIFIC PROGRAMME

Complex pelvic fistula revisited: established wisdom and innovative approaches

Anorectal trauma and foreign bodies

Sexually transmitted diseases in proctology

The painful bottom – Proctalgia beyond the classical abscess, fissures, and hemorrhoids

Fecal incontinence: investigations and conservative treatment

Fecal incontinence: neuromodulation and surgical options

The pelvic floor revealed: investigations and conservative management

The pelvic floor revealed: transperineal / transvaginal / transanal repairs explained

Obstructed defecation and IBS: investigations and differential diagnosis

Obstructed defecation: surgical options

Obstretical trauma: assessment, timing and options to repair

Mind and bottom reunited – from abuse to psychoproctology

Urogenital dysfunction in patients treated for rectal cancer – what do we know and what can we do?

Strategies and outcomes for obstructive cancers of the colon and rectum

The septic abdomen: getting out of misery and closing the case

Lars Pahlman lecture: Extending the limits of liver surgery

Do resection of the mesentery in Crohn's & appendectomy in ulcerative colitis alter the course of disease

Anal pain and emergency proctology: what every surgeon should know & do

Ventral rectopexy: indications, tricks of the trade, and long-term results

Randomized trial evaluating chemotherapy followed by pelvic reirradiation vs chemotherapy alone as preoperative treatment for locally recurrent rectal cancer (GRECCAR 15)

Kono S anastomosis and over the valve stricturoplasties: hope for better outcomes

Ethical considerations in crisis – lessons from Covid-19

Hemorrhoids – new options and time-tested solutions Multimodal approaches to colorectal liver metastases

Timeline of surgery following neoadjuvant radiotherapy – balancing morbidity and efficacy

Management pearls for early rectal cancer

Lessons learned along the robotic learning curve: a video guide for colorectal surgeons

Place and outcome of total colectomy in the surgical armamentarium

Total neoadjuvant therapy for colon and rectum cancers

Enhanced recovery pathways reloaded – a practical guide to success



EAES presidential lecture: Strategies for lifelong learning and implementation of new technologies

Is cancer an infectious disease: role of the microbiome

All you need to know about anorectal fistula

New drugs, old fears: state of the art management of IBD patients

A journey in global surgery – why getting out of the comfort zone

Anastomotic leak in colorectal surgery: insights, perspectives, and practical strategies

Management strategies for patients with advanced colorectal cancers

Cancer at the extremes of age: are there any differences in handling youngsters and seniors

## Information & Registration

[www.colorectalsurgery.eu](http://www.colorectalsurgery.eu)

The publication of this advertisement does not constitute endorsement by the society, publisher, or Editors, and is unrelated to the content that follows

# Rates of re-excision and conversion to mastectomy after breast-conserving surgery with or without oncoplastic surgery: a nationwide population-based study

E. Heeg<sup>1,2</sup> , M. B. Jensen<sup>4</sup>, L. R. Hölmich<sup>6</sup>, A. Bodilsen<sup>7</sup>, R. A. E. M. Tollenaar<sup>2</sup>, A. V. Lækholm<sup>10</sup>, B. V. Offersen<sup>8</sup>, B. Ejlersen<sup>4,5</sup> , M. A. M. Mureau<sup>3</sup> and P. M. Christiansen<sup>9</sup>

<sup>1</sup>Dutch Institute for Clinical Auditing, and <sup>2</sup>Department of Surgery, Leiden University Medical Centre, Leiden, and <sup>3</sup>Department of Plastic and Reconstructive Surgery, Erasmus MC Cancer Institute, University Medical Centre Rotterdam, Rotterdam, the Netherlands, <sup>4</sup>Danish Breast Cancer Cooperative Group, and <sup>5</sup>Department of Oncology, Rigshospitalet, Copenhagen, <sup>6</sup>Department of Plastic Surgery, Herlev Gentofte Hospital, Herlev, Departments of <sup>7</sup>Surgery, <sup>8</sup>Oncology and <sup>9</sup>Plastic and Breast Surgery, Aarhus University Hospital, Aarhus, and <sup>10</sup>Department of Surgical Pathology, Zealand University Hospital, Slagelse, Denmark

Correspondence to: Dr E. Heeg, Danish Breast Cancer Cooperative Group, Blegdamsvej 9, Copenhagen DK2100, Denmark (e-mail: e.heeg@lumc.nl)

**Background:** There is no consensus regarding the impact of oncoplastic surgery (OPS) on rates of re-excision and conversion to mastectomy following breast-conserving surgery (BCS). Here these two outcomes after BCS and OPS were compared in a nationwide population-based setting.

**Methods:** In Denmark, all OPS is registered and categorized into volume displacement, volume reduction or volume replacement. Patients who underwent BCS or OPS between 2012 and 2018 were selected from the Danish Breast Cancer Group database. Multivariable analyses were performed to adjust for confounders, and propensity score matching to limit potential confounding by indication bias.

**Results:** A total of 13 185 patients (72.5 per cent) underwent BCS and 5003 (27.5 per cent) OPS. Volume displacement was used in 4171 patients (83.4 per cent), volume reduction in 679 (13.6 per cent) and volume replacement in 153 (3.1 per cent). Re-excision rates were 15.6 and 14.1 per cent after BCS and OPS respectively. After adjusting for confounders, patients were less likely to have a re-excision following OPS than BCS (odds ratio (OR) 0.80, 95 per cent c.i. 0.72 to 0.88), specifically after volume displacement and reduction. The rate of conversion to mastectomy was similar after OPS and BCS (3.2 versus 3.7 per cent;  $P = 0.105$ ), but with a lower risk in adjusted analysis (OR 0.69, 0.58 to 0.84), specifically after volume displacement and reduction procedures. Findings were similar after propensity score matching.

**Conclusion:** A modest decrease in re-excision rate and less frequent conversion to mastectomy were observed after OPS compared with BCS.

Paper accepted 31 May 2020

Published online in Wiley Online Library (www.bjs.co.uk). DOI: 10.1002/bjs.11838

## Introduction

Randomized trials<sup>1–5</sup> conducted in the 1980s established breast-conserving surgery (BCS) followed by radiotherapy as the preferred treatment for early-stage breast cancer. Improved breast cancer survival rates<sup>6,7</sup> have led to an increased focus on cosmetic outcomes after treatment<sup>8</sup>. Consequently, a challenging balance has emerged between achieving complete resection of the tumour with appropriate tumour-free margins and a favourable cosmetic result. Not every patient is eligible for BCS owing to anatomical and tumour characteristics<sup>9</sup>.

Oncoplastic surgery (OPS) improves cosmetic outcomes and is nowadays used in up to 34 per cent of patients with

breast cancer undergoing BCS<sup>10–14</sup>. Previous studies<sup>15,16</sup> have demonstrated that by using OPS breast conservation becomes an alternative to mastectomy in patients with large and multifocal tumours. Compared with BCS, OPS is associated with larger resections<sup>17,18</sup>, and good long-term survival outcomes<sup>11,13,18,19</sup> and quality of life<sup>20–22</sup>. Achieving larger tumour resections with OPS may also reduce the number of re-excisions owing to insufficient margins. High-quality evidence regarding the impact of OPS on re-excisions is, however, sparse<sup>18,19</sup>.

Between 2000 and 2009, re-excision after BCS occurred in about 17 per cent of patients with breast cancer in Denmark<sup>23</sup>, which is within the reported range of 5–35

per cent<sup>22,24–26</sup>. Re-excision requiring mastectomy is commonly defined as conversion to mastectomy. Re-excision and conversion to mastectomy are associated with more morbidity, complications, poorer aesthetic outcome, greater patient distress and increased healthcare costs<sup>27,28</sup>. Furthermore, for patients in whom free margins were not achieved during primary BCS, an increased risk of ipsilateral breast tumour recurrence has been reported<sup>23</sup>.

In Denmark, OPS techniques have been registered prospectively by the Danish Breast Cancer Group (DBCG) for all patients undergoing BCS since July 2010. The primary goal of the present study was to compare re-excision rates after BCS *versus* OPS in patients with early-stage breast cancer, in a population-based national setting. A further aim was to investigate whether OPS results in a lower conversion to mastectomy rate (CMR) than BCS. As several studies<sup>11–13,29</sup> have shown that patients may not have the same likelihood of receiving OPS based on their baseline characteristics, additional propensity score matching was used to limit the potential confounding by indication bias.

## Methods

Since 1978, the DBCG has collected clinicopathological and treatment characteristics and follow-up data prospectively from all patients diagnosed with a primary invasive breast cancer<sup>30</sup>. OPS is categorized into three types: volume displacement, defined as local rearrangement of tissue near the lumpectomy cavity in order to close the defect; volume reduction, defined as the use of a breast reduction technique to remove tumour and improve breast shape at the same time; and volume replacement, defined as tissue transfer from outside the breast into the breast (such as local perforator flaps). A more detailed description of data collection by the DBCG has been published<sup>30,31</sup>. The study was approved by the Scientific Committee of Surgery within the DBCG and the Danish Clinical Registries.

## Study population

All women with invasive breast cancer without distant metastasis, who underwent primary BCS between January 2012 and December 2018, identified from the DBCG database were included. Patients who received neoadjuvant therapy or surgical biopsy as the only surgical procedure were excluded. Patients were categorized into four groups: BCS (without OPS), OPS with volume displacement, OPS with volume reduction, and OPS with volume replacement.

## Outcomes

The primary outcome was re-excision, defined as a second BCS procedure or mastectomy following the primary BCS within 2 months of the initial operation. This interval was chosen to limit potential re-excisions owing to breast cancer recurrence. Information about re-excision, including type, was retrieved from Danish National Patient Registry<sup>32</sup>. Re-excision rates among patients aged over 50 years might be influenced by use of boost radiation for treatment of insufficient margins, so secondary interventions (re-excision or boost radiation) were compared in patients aged 50 years or older undergoing BCS or OPS. The secondary outcome, CMR, was defined as the rate of mastectomy following the primary BCS within 2 months of the initial operation.

## Confounders

Co-morbidity was classified according to the Charlson Co-morbidity Index (CCI)<sup>33</sup>. Histological subtypes, such as papillary, medullary and mucinous subtypes, were categorized as 'other'. In Denmark, grading is applied to invasive ductal and lobular carcinomas, but not to subtypes classified as 'other', according to the modified version of the Bloom Richardson scoring system of Elston and Ellis<sup>34</sup>. Breast cancer was classified as oestrogen receptor-positive when at least 10 per cent of cells stained positive in immunohistochemical analyses. Expression of human epidermal growth factor receptor 2 (HER2) was determined according to standard recommendations<sup>35</sup>. Tumour size and lymph node status were categorized according to the seventh edition of the AJCC cancer staging classification<sup>36</sup>. Any missing characteristics were classified as unknown.

## Guidelines

In accordance with Danish guidelines<sup>30,31</sup>, re-excision was advised if invasive carcinoma was identified at the inked margins or ductal carcinoma *in situ* (DCIS) within 2 mm from the margin. Danish guidelines also recommend boost radiation in all patients younger than 50 years after BCS with or without OPS; and in those with a microscopic free margin of less than 2 mm for invasive breast cancer or DCIS, irrespective of age<sup>37,38</sup>.

## Statistical analysis

Patient and tumour characteristics were compared between BCS and OPS groups using  $\chi^2$  test for categorical variables, and Mann–Whitney *U* test or Kruskal–Wallis test for continuous variables. Unknown characteristics were included



in the descriptive statistics. Two-sided  $P < 0.050$  was considered statistically significant. To adjust for confounders, a multivariable logistic regression model was used to estimate whether patients who underwent OPS were more likely to have a re-excision than those who had BCS. Results were expressed as odds ratios (ORs) with 95 per cent confidence intervals, and the Wald test was used for analysis of statistical significance. The latter analyses were repeated for the secondary outcome CMR. Patients with unknown variables were included as a separate category in all analyses.

To evaluate whether associations were subject to confounding by indication, meaning that not all patients were equally likely to have received OPS, analyses were repeated in propensity score-matched cohorts. Patients who underwent BCS were matched with those who had OPS as a whole and by each type of OPS. Patients were matched on the likelihood of undergoing OPS using the following co-variables: year of operation, age, CCI score, histological finding, differentiation grade, oestrogen receptor positivity, HER2 status, T and N status<sup>39,40</sup>. Patients who underwent BCS were matched 1 : 1 with those who had OPS using a caliper width of 0.2 times the standard deviation of the logit of the propensity score<sup>41</sup>. Potential imbalances in characteristics before and after matching were shown using a standardized difference; a value of 10 per cent or more was indicative of an imbalance in characteristics<sup>42</sup>. All analyses were performed using SPSS® version 24 (IBM, Armonk, New York, USA).

## Results

A total of 18 188 patients met the inclusion criteria, of whom 13 185 (72.5 per cent) underwent BCS and 5003 (27.5 per cent) OPS. Patients who had BCS were older than those who had OPS (mean(s.d.) 62.1(11.5) *versus* 59.9(11.5) years;  $P < 0.001$ ) (Table 1). Patients who underwent OPS had a lower co-morbidity score than those who had BCS ( $P < 0.001$ ), but poorer prognostic tumour factors, including higher differentiation grade ( $P < 0.001$ ), larger tumour size ( $P < 0.001$ ) and more lymph node involvement ( $P < 0.001$ ). The use of OPS decreased significantly from 30.3 per cent in 2012 to 26.4 per cent in 2018 ( $P < 0.001$ ).

OPS was performed with volume displacement in 4171 patients (83.4 per cent), volume reduction in 679 (13.6 per cent) and volume replacement in 153 (3.1 per cent). Patients who underwent OPS with volume reduction or replacement had lower co-morbidity scores ( $P = 0.020$ ), larger tumours ( $P < 0.001$ ) and more lymph node involvement ( $P < 0.001$ ) than those who had volume displacement

(Table 2). Baseline characteristics of patients who underwent the three types of OPS are provided in Table 2.

In total, 2763 patients (15.2 per cent) underwent re-excision, in whom the final surgical treatment was BCS in 2108 patients (76.3 per cent) and mastectomy in 655 (23.7 per cent). The re-excision rate was 15.6 per cent for patients who underwent BCS and 14.1 per cent among those who had OPS ( $P = 0.012$ ). Re-excision rates varied according to OPS technique: 14.5 per cent for volume displacement, 10.3 per cent for volume reduction and 20.9 per cent for volume replacement (Table 3). The unadjusted re-excision rate did not change significantly over time ( $P = 0.438$ ).

Multivariable analysis showed that patients who underwent OPS were less likely to undergo re-excision than those who had BCS (adjusted OR 0.80, 95 per cent c.i. 0.72 to 0.88). Subsequent analyses showed that patients who underwent OPS with volume displacement (OR 0.83, 0.75 to 0.92) or volume reduction (OR 0.50, 0.39 to 0.65) were less likely to undergo re-excision than those who had BCS (Table 3). Patients who underwent OPS with volume replacement had the same likelihood of re-excision as the BCS group (OR 1.16, 0.78 to 1.73).

Other characteristics associated with re-excision were lobular or other histological subtype, higher differentiation grade, unknown oestrogen receptor status, positive HER2 status, larger tumour size and lymph node involvement (Table 3). Re-excisions were less likely with increasing age. Year of surgery and co-morbidity were not associated with re-excision.

A shift from an imbalance in characteristics before propensity score matching to a balance after matching was observed when the BCS group was matched with the OPS group as a whole, and by type of OPS (Tables S1–S4, supporting information). In the matched cohort with OPS as a whole, re-excision was less likely after OPS than BCS (OR 0.79, 0.71 to 0.88), similar to the results of multivariable analysis of the unmatched study population. Matched patients who underwent OPS with volume displacement (OR 0.80, 0.71 to 0.90) or volume reduction (0.46, 0.34 to 0.63) were less likely to undergo re-excision than the BCS group, whereas patients who underwent OPS with volume replacement had the same likelihood of re-excision as patients who had BCS (OR 1.13, 0.65 to 1.98).

Further analyses showed similar use of secondary interventions in patients older than 50 years undergoing BCS or OPS (16.4 *versus* 15.9 per cent;  $P = 0.430$ ). However, among patients who had secondary interventions, boost radiation was used less often in patients who underwent BCS compared with those who had OPS (14.7 *versus* 21.2 per cent;  $P < 0.001$ ).

| <b>Table 1 Baseline characteristics of patients who underwent breast-conserving surgery or oncoplastic surgery</b> |                                  |                         |                       |           |
|--|----------------------------------|-------------------------|-----------------------|-----------|
|  | <b>All patients (n = 18 188)</b> | <b>BCS (n = 13 185)</b> | <b>OPS (n = 5003)</b> | <b>P†</b> |
| <b>Year of operation</b>   |                                  |                         |                       | < 0.001   |
| 2012   | 2667 (14.7)                      | 1858 (14.1)             | 809 (16.2)            |           |
| 2013   | 2733 (15.0)                      | 2052 (15.6)             | 681 (13.6)            |           |
| 2014   | 2751 (15.1)                      | 1933 (14.7)             | 818 (16.4)            |           |
| 2015   | 2626 (14.4)                      | 1909 (14.5)             | 717 (14.3)            |           |
| 2016   | 2533 (13.9)                      | 1852 (14.0)             | 681 (13.6)            |           |
| 2017   | 2476 (13.6)                      | 1813 (13.8)             | 663 (13.3)            |           |
| 2018   | 2402 (13.2)                      | 1768 (13.4)             | 634 (12.7)            |           |
| <b>Age (years)*</b>  | 61.5(11.5)                       | 62.1(11.5)              | 59.9(11.5)            | < 0.001‡  |
| <b>Charlson Co-morbidity Index score</b>   |                                  |                         |                       | < 0.001   |
| 0  | 13 987 (76.9)                    | 9942 (75.4)             | 4045 (80.9)           |           |
| 1  | 2500 (13.7)                      | 1910 (14.5)             | 590 (11.8)            |           |
| 2  | 1118 (6.1)                       | 868 (6.6)               | 250 (5.0)             |           |
| ≥ 3  | 583 (3.2)                        | 465 (3.5)               | 118 (2.4)             |           |
| <b>Histological finding</b>  |                                  |                         |                       | < 0.001   |
| Ductal   | 14 777 (81.2)                    | 10 669 (80.9)           | 4108 (82.1)           |           |
| Lobular  | 1888 (10.4)                      | 1339 (10.2)             | 549 (11.0)            |           |
| Other  | 1505 (8.3)                       | 1161 (8.8)              | 344 (6.9)             |           |
| Unknown  | 18 (0.1)                         | 16 (0.1)                | 2 (0.0)               |           |
| <b>Differentiation grade</b>   |                                  |                         |                       | < 0.001   |
| I  | 4809 (26.4)                      | 3683 (27.9)             | 1126 (22.5)           |           |
| II   | 7958 (43.8)                      | 5700 (43.2)             | 2258 (45.1)           |           |
| III  | 3747 (20.6)                      | 2496 (18.9)             | 1251 (25.0)           |           |
| Not determined   | 1505 (8.3)                       | 1161 (8.8)              | 344 (6.9)             |           |
| Unknown  | 169 (0.9)                        | 145 (1.1)               | 24 (0.5)              |           |
| <b>Oestrogen receptor (%)</b>  |                                  |                         |                       | < 0.001   |
| < 10   | 2272 (12.5)                      | 1562 (11.8)             | 710 (14.2)            |           |
| ≥ 10   | 15 867 (87.2)                    | 11 583 (87.8)           | 4284 (85.6)           |           |
| Unknown  | 49 (0.3)                         | 40 (0.3)                | 9 (0.2)               |           |
| <b>HER2 status</b>   |                                  |                         |                       | < 0.001   |
| Negative   | 16 086 (88.4)                    | 11 751 (89.1)           | 4335 (86.6)           |           |
| Positive   | 1916 (10.5)                      | 1281 (9.7)              | 635 (12.7)            |           |
| Unknown  | 186 (1.0)                        | 153 (1.2)               | 33 (0.7)              |           |
| <b>T category</b>  |                                  |                         |                       | < 0.001   |
| T1   | 14 302 (78.6)                    | 10 854 (82.3)           | 3448 (68.9)           |           |
| T2   | 3790 (20.8)                      | 2264 (17.2)             | 1526 (30.5)           |           |
| T3   | 85 (0.5)                         | 57 (0.4)                | 28 (0.6)              |           |
| Unknown  | 11 (0.1)                         | 10 (0.1)                | 1 (0.0)               |           |
| <b>N category</b>  |                                  |                         |                       | < 0.001   |
| N0   | 12 649 (69.5)                    | 9397 (71.3)             | 3252 (65.0)           |           |
| N1   | 4220 (23.2)                      | 2818 (21.4)             | 1402 (28.0)           |           |
| N2   | 673 (3.7)                        | 436 (3.3)               | 237 (4.7)             |           |
| N3   | 313 (1.7)                        | 226 (1.7)               | 87 (1.7)              |           |
| Unknown  | 333 (1.8)                        | 308 (2.3)               | 25 (0.5)              |           |

Values in parentheses are percentages unless indicated otherwise; \*values are mean(s.d.). BCS, breast-conserving surgery; OPS, oncoplastic surgery; HER2, human epidermal growth factor receptor 2. † $\chi^2$  test, except ‡Mann–Whitney *U* test.

Impact of oncoplastic surgery on rates of re-excision and conversion to mastectomy

| Table 2 Baseline characteristics according to type of oncoplastic surgery |                                   |                               |                                 |         |
|---|-----------------------------------|-------------------------------|---------------------------------|---------|
|   | Volume displacement<br>(n = 4171) | Volume reduction<br>(n = 679) | Volume replacement<br>(n = 153) | P†      |
| <b>Year of operation</b>  |                                   |                               |                                 |         |
| 2012  | 658 (15.8)                        | 113 (16.6)                    | 38 (24.8)                       | < 0.001 |
| 2013  | 536 (12.9)                        | 119 (17.5)                    | 26 (17.0)                       |         |
| 2014  | 680 (16.3)                        | 111 (16.3)                    | 27 (17.6)                       |         |
| 2015  | 609 (14.6)                        | 88 (13.0)                     | 20 (13.1)                       |         |
| 2016  | 561 (13.5)                        | 97 (14.3)                     | 23 (15.0)                       |         |
| 2017  | 583 (14.0)                        | 72 (10.6)                     | 8 (5.2)                         |         |
| 2018  | 544 (13.0)                        | 79 (11.6)                     | 11 (7.2)                        |         |
| <b>Age (years)*</b>   | 60.1(11.5)                        | 58.9(11.2)                    | 57.4(10.3)                      |         |
| <b>Charlson Co-morbidity Index score</b>                                  |                                   |                               |                                 |         |
| 0   | 3355 (80.4)                       | 557 (82.0)                    | 133 (86.9)                      | 0.020   |
| 1   | 515 (12.3)                        | 63 (9.3)                      | 12 (7.8)                        |         |
| 2   | 198 (4.7)                         | 44 (6.5)                      | 8 (5.2)                         |         |
| ≥ 3   | 103 (2.5)                         | 15 (2.2)                      | 0 (0)                           |         |
| <b>Histological finding</b>   |                                   |                               |                                 |         |
| Ductal  | 3418 (81.9)                       | 563 (82.9)                    | 127 (83.0)                      | 0.909   |
| Lobular   | 456 (10.9)                        | 75 (11.0)                     | 18 (11.8)                       |         |
| Other   | 295 (7.1)                         | 41 (6.0)                      | 8 (5.2)                         |         |
| Unknown   | 2 (0.0)                           | 0 (0)                         | 0 (0)                           |         |
| <b>Differentiation grade</b>  |                                   |                               |                                 |         |
| I   | 963 (23.1)                        | 131 (19.3)                    | 32 (20.9)                       | 0.071   |
| II  | 1884 (45.2)                       | 299 (44.0)                    | 75 (49.0)                       |         |
| III   | 1010 (24.2)                       | 204 (30.0)                    | 37 (24.2)                       |         |
| Not determined  | 295 (7.1)                         | 41 (6.0)                      | 8 (5.2)                         |         |
| Unknown   | 19 (0.5)                          | 4 (0.6)                       | 1 (0.7)                         |         |
| <b>Oestrogen receptor (%)</b>   |                                   |                               |                                 |         |
| < 10  | 592 (14.2)                        | 95 (14.0)                     | 23 (15.0)                       | 0.752   |
| ≥ 10  | 3570 (85.6)                       | 584 (86.0)                    | 130 (85.0)                      |         |
| Unknown   | 9 (0.2)                           | 0 (0)                         | 0 (0)                           |         |
| <b>HER2 status</b>  |                                   |                               |                                 |         |
| Negative  | 3620 (86.8)                       | 581 (85.6)                    | 134 (87.6)                      | 0.721   |
| Positive  | 522 (12.5)                        | 94 (13.8)                     | 19 (12.4)                       |         |
| Unknown   | 29 (0.7)                          | 4 (0.6)                       | 0 (0)                           |         |
| <b>T category</b>   |                                   |                               |                                 |         |
| T1  | 3000 (71.9)                       | 370 (54.5)                    | 78 (51.0)                       | < 0.001 |
| T2  | 1152 (27.6)                       | 300 (44.2)                    | 74 (48.4)                       |         |
| T3  | 18 (0.4)                          | 9 (1.3)                       | 1 (0.7)                         |         |
| Unknown   | 1 (0.0)                           | 0 (0)                         | 0 (0)                           |         |
| <b>N category</b>   |                                   |                               |                                 |         |
| N0  | 2749 (65.9)                       | 417 (61.4)                    | 86 (56.2)                       | 0.006   |
| N1  | 1134 (27.2)                       | 215 (31.7)                    | 53 (34.6)                       |         |
| N2  | 190 (4.6)                         | 39 (5.7)                      | 8 (5.2)                         |         |
| N3  | 74 (1.8)                          | 7 (1.0)                       | 6 (3.9)                         |         |
| Unknown   | 24 (0.6)                          | 1 (0.1)                       | 0 (0)                           |         |

Values in parentheses are percentages unless indicated otherwise; \*values are mean(s.d.). HER2, human epidermal growth factor receptor 2. † $\chi^2$  test, except ‡Kruskal–Wallis test.

| Table 3 Univariable and multivariable logistic regression analyses of characteristics predictive of re-excision |                    |                   |                                      |  |                |
|---|--------------------|-------------------|--------------------------------------|--|----------------|
|   | Re-excision        |                   | Odds ratio <sup>†</sup>              |  | P <sup>‡</sup> |
|   | No<br>(n = 15 425) | Yes<br>(n = 2763) | Univariable<br>analysis (n = 18 188) | Multivariable<br>analysis (n = 18 188) |                |
| <b>Type of surgery</b>  |                    |                   |                                      |  | < 0.001        |
| BCS   | 11 128 (84.4)      | 2057 (15.6)       | 1.00 (reference)                     | 1.00 (reference)                       |                |
| Volume displacement   | 3567 (85.5)        | 604 (14.5)        | 0.92 (0.83, 1.01)                    | 0.83 (0.75, 0.92)                      |                |
| Volume reduction  | 609 (89.7)         | 70 (10.3)         | 0.62 (0.48, 0.80)                    | 0.50 (0.39, 0.65)                      |                |
| Volume replacement  | 121 (79.1)         | 32 (20.9)         | 1.43 (0.97, 2.12)                    | 1.16 (0.78, 1.73)                      |                |
| <b>Year of operation</b>  |                    |                   |                                      |  | 0.202          |
| 2012  | 2295 (86.1)        | 372 (13.9)        | 1.00 (reference)                     | 1.00 (reference)                       |                |
| 2013  | 2332 (85.3)        | 401 (14.7)        | 1.06 (0.91, 1.24)                    | 1.07 (0.92, 1.25)                      |                |
| 2014  | 2330 (84.7)        | 421 (15.3)        | 1.12 (0.96, 1.30)                    | 1.12 (0.96, 1.31)                      |                |
| 2015  | 2208 (84.1)        | 418 (15.9)        | 1.17 (1.00, 1.36)                    | 1.19 (1.02, 1.39)                      |                |
| 2016  | 2144 (84.6)        | 389 (15.4)        | 1.12 (0.96, 1.31)                    | 1.13 (0.97, 1.33)                      |                |
| 2017  | 2083 (84.1)        | 393 (15.9)        | 1.16 (1.00, 1.36)                    | 1.21 (1.04, 1.42)                      |                |
| 2018  | 2033 (84.6)        | 369 (15.4)        | 1.12 (0.96, 1.31)                    | 1.19 (1.01, 1.39)                      |                |
| <b>Age (years)*</b>   | 61.8(11.6)         | 59.9(11.2)        | 0.99 (0.98, 0.99)                    | 0.99 (0.98, 0.99)                      | < 0.001        |
| <b>Charlson Co-morbidity Index score</b>  |                    |                   |                                      |  | 0.061          |
| 0   | 11 790 (84.3)      | 2197 (15.7)       | 1.00 (reference)                     | 1.00 (reference)                       |                |
| 1   | 2148 (85.9)        | 352 (14.1)        | 0.88 (0.78, 0.99)                    | 0.94 (0.83, 1.07)                      |                |
| 2   | 962 (86.0)         | 156 (14.0)        | 0.87 (0.73, 1.04)                    | 0.96 (0.81, 1.15)                      |                |
| ≥ 3   | 525 (90.1)         | 58 (9.9)          | 0.59 (0.45, 0.78)                    | 0.69 (0.52, 0.91)                      |                |
| <b>Histological finding</b>   |                    |                   |                                      |  | < 0.001        |
| Ductal  | 12 614 (85.4)      | 2163 (14.6)       | 1.00 (reference)                     | 1.00 (reference)                       |                |
| Lobular   | 1527 (80.9)        | 361 (19.1)        | 1.38 (1.22, 1.56)                    | 1.40 (1.23, 1.59)                      |                |
| Other   | 1269 (84.3)        | 236 (15.7)        | 1.09 (0.94, 1.26)                    | 1.45 (1.22, 1.71)                      |                |
| Unknown   | 15 (83.3)          | 3 (16.7)          | 1.17 (0.34, 4.03)                    | 0.18 (0.04, 0.78)                      |                |
| <b>Differentiation grade</b>  |                    |                   |                                      |  | < 0.001        |
| I   | 4246 (88.3)        | 563 (11.7)        | 1.00 (reference)                     | 1.00 (reference)                       |                |
| II  | 6658 (83.7)        | 1300 (16.3)       | 1.35 (1.23, 1.48)                    | 1.32 (1.19, 1.47)                      |                |
| III   | 3141 (83.8)        | 606 (16.2)        | 1.33 (1.19, 1.49)                    | 1.18 (1.03, 1.36)                      |                |
| Not determined  | 1269 (84.3)        | 236 (15.7)        | –                                    | –                                      |                |
| Unknown   | 111 (65.7)         | 58 (34.3)         | 3.61 (2.60, 5.00)                    | 3.69 (2.57, 5.30)                      |                |
| <b>Oestrogen receptor (%)</b>   |                    |                   |                                      |  | 0.005          |
| < 10  | 1902 (83.7)        | 370 (16.3)        | 1.10 (0.98, 1.24)                    | 0.97 (0.85, 1.12)                      |                |
| ≥ 10  | 13 490 (85.0)      | 2377 (15.0)       | 1.00 (reference)                     | 1.00 (reference)                       |                |
| Unknown   | 33 (67.3)          | 16 (32.7)         | 2.75 (1.51, 5.01)                    | 3.69 (1.66, 8.21)                      |                |
| <b>HER2 status</b>  |                    |                   |                                      |  | < 0.001        |
| Negative  | 13 775 (85.6)      | 2311 (14.4)       | 1.00 (reference)                     | 1.00 (reference)                       |                |
| Positive  | 1496 (78.1)        | 420 (21.9)        | 1.67 (1.49, 1.88)                    | 1.60 (1.42, 1.81)                      |                |
| Unknown   | 154 (82.8)         | 32 (17.2)         | 1.24 (0.84, 1.82)                    | 0.85 (0.52, 1.38)                      |                |
| <b>T category</b>   |                    |                   |                                      |  | < 0.001        |
| T1  | 12 284 (85.9)      | 2018 (14.1)       | 1.00 (reference)                     | 1.00 (reference)                       |                |
| T2  | 3097 (81.7)        | 693 (18.3)        | 1.36 (1.24, 1.50)                    | 1.33 (1.20, 1.48)                      |                |
| T3  | 37 (43.5)          | 48 (56.5)         | 7.90 (5.13, 12.16)                   | 7.16 (4.58, 11.18)                     |                |
| Unknown   | 7 (63.6)           | 4 (36.4)          | 3.48 (1.02, 11.89)                   | 2.58 (0.64, 10.37)                     |                |
| <b>N category</b>   |                    |                   |                                      |  | < 0.001        |
| N0  | 10 865 (85.9)      | 1784 (14.1)       | 1.00 (reference)                     | 1.00 (reference)                       |                |
| N1  | 3501 (83.0)        | 719 (17.0)        | 1.25 (1.14, 1.38)                    | 1.20 (1.09, 1.33)                      |                |
| N2  | 521 (77.4)         | 152 (22.6)        | 1.78 (1.47, 2.14)                    | 1.51 (1.24, 1.84)                      |                |
| N3  | 243 (77.6)         | 70 (22.4)         | 1.75 (1.34, 2.30)                    | 1.39 (1.05, 1.84)                      |                |
| Unknown   | 295 (88.6)         | 38 (11.4)         | 0.79 (0.59, 1.10)                    | 0.75 (0.52, 1.09)                      |                |

Values in parentheses are percentages unless indicated otherwise; \*values are mean(s.d.) and †values in parentheses are 95 per cent confidence intervals. BCS, breast-conserving surgery; HER2, human epidermal growth factor receptor 2. †Adjusted for type of surgery, year of operation, age, histological finding, differentiation grade, oestrogen receptor, HER2 status, T and N category. ‡Wald test.

In total, conversion to mastectomy was performed in 655 patients (3.6 per cent). The CMR was 3.7 and 3.2 per cent after BCS and OPS respectively ( $P = 0.105$ ). Different CMRs were observed among the OPS techniques: 3.2 per cent for volume displacement, 2.9 per cent for volume reduction and 5.9 per cent for volume replacement. Over time, the unadjusted CMR decreased significantly from 4.3 to 2.7 per cent ( $P = 0.003$ ) (Table S5, supporting information).

Multivariable analysis showed that patients who underwent OPS were less likely to undergo conversion to mastectomy than those who had BCS (OR 0.69, 0.58 to 0.84). Similar results were found for subgroups who had OPS with volume displacement (OR 0.71, 0.58 to 0.87) or volume reduction (OR 0.53, 0.33 to 0.84) (Table S5, supporting information). There was no difference in CMR between OPS with volume replacement and BCS (OR 1.07, 0.53 to 2.13). Conversion to mastectomy was more likely in patients with poor prognostic characteristics, including lobular histology ( $P < 0.001$ ), larger tumour ( $P < 0.001$ ) and more lymph node involvement ( $P < 0.001$ ). In the matched cohorts (Tables S1–S4, supporting information), results of multivariable analyses were similar to those for the unmatched groups, in comparisons of OPS as a whole versus BCS (OR 0.70, 0.57 to 0.86), and OPS with volume displacement (OR 0.67, 0.54 to 0.84), volume reduction (OR 0.51, 0.30 to 0.89) or volume replacement (OR 1.13, 0.43 to 3.02) versus BCS.

## Discussion

In this population-based cohort study, re-excision or conversion to mastectomy was less likely among patients who underwent OPS than BCS, although differences were modest. The re-excision rate and CMR were lower among patients who underwent OPS using volume displacement and reduction techniques, but both rates were similar after BCS and OPS with volume replacement, although numbers in the latter group were small. This large population-based study adjusted for confounders, and limited confounding by indication bias by means of propensity score matching.

Although no long-term differences in recurrence rates and survival between BCS and OPS have been reported<sup>13,19,22,43–45</sup>, current evidence regarding the impact of OPS on the re-excision rate is limited because the data are from single-centre studies with relatively few patients undergoing OPS (ranging from 31 to 1177), and in most studies the methodology was weak<sup>11,13,44,46–48</sup>. The present results are in line with a meta-analysis<sup>19</sup> from 2018 that found a significantly lower risk of re-excision in

patients who underwent OPS compared with those who had BCS (relative risk 0.66, 95 per cent c.i. 0.48 to 0.90). However, more recently, comparable re-excision rates after BCS and OPS were reported in two studies from Finland<sup>13</sup> and Iceland<sup>11</sup>. In contrast to the present study, only relatively small numbers of patients were included, without extensive adjustment for confounders.

Since 2011, Danish guidelines<sup>31</sup> have stated that OPS should be considered when, for example, tumour size and location do not allow a satisfactory cosmetic result with BCS. In the present study, use of OPS among patients who underwent BCS decreased between 2012 and 2018 (from 30.3 to 26.4 per cent), specifically in volume reduction and replacement techniques. A large multicentre study<sup>10</sup> from the USA showed a significant rise in the OPS rate from 4.3 to 9.0 per cent between 2005 and 2016. Among those who underwent OPS, the percentage who had volume displacement was similar to that in the present study (85.2 and 83.4 per cent respectively). Nonetheless, the overall use of OPS here was still substantially higher than in most previous studies<sup>18,19</sup>.

Boost radiation is associated with serious side-effects such as fibrosis, radiation heart disease and second non-breast cancers<sup>49,50</sup>, and so re-excision may have been preferred over boost radiation, specifically in patients with a tumour bed in front of the heart<sup>51</sup>. Nonetheless, in the present study, the rate of secondary interventions among patients older than 50 years was similar in those undergoing BCS and OPS, although boost radiation was preferred to re-excision in the event of insufficient margins for those who underwent OPS. This was slightly surprising, as radiotherapy planning is challenging after OPS, because identification of the tumour bed can be difficult<sup>52</sup>. These findings highlight the challenge in balancing morbidity from re-excision with that of boost radiation, and the importance of close collaboration between surgeons and radiation oncologists. Any decision regarding re-excision or boost radiation should be made at a multidisciplinary team meeting.

Heterogeneous definitions of insufficient margins, ranging from 'tumour within 10 mm from the ink margin' to 'tumour on ink', may partly explain the difference between the findings here and those of other studies<sup>18,19</sup>. The present overall re-excision rate of 15.2 per cent is within the range (0–15.7 per cent) reported in other studies<sup>13,53–55</sup> that used the same definition of 'tumour on ink'. The associations between poor prognostic factors, such as larger tumour or lymph node involvement, and re-excision and conversion to mastectomy are in line with previous findings<sup>18,53,55</sup>. Future guidelines may highlight the additional risk when considering OPS in these patients.



The overall CMR of 3.6 per cent in this analysis is well below the mean of 6.2 per cent and within the range of 0–34.2 per cent reported in previous studies, and a systematic review<sup>18</sup> of 55 studies. However, it is not in line with the results of a meta-analysis<sup>17</sup> from 2014, which found a higher CMR for OPS with volume reduction and volume replacement compared with BCS. This may be explained partly by the fact that most included studies did not adjust for confounders and did not exclude patients diagnosed with *in situ* disease alone, because such patients are less likely to have a re-excision rate similar to that for invasive breast cancer<sup>56</sup>.

The differing rates of re-excision between OPS techniques might be explained by the small absolute numbers, and consequently wide confidence intervals. Another explanation could be differences in patient or tumour factors used for surgical procedure selection. Breast and tumour size, tumour location and glandular density are, among other factors, used in selection of the preferred OPS technique<sup>16,57</sup>, but also affect the likelihood of having a secondary mastectomy. For instance, patients with smaller breasts who require OPS with volume replacement may be less eligible for a secondary BCS, and may therefore undergo a secondary mastectomy when indicated.

The present data support the theory that OPS is associated with fewer re-excisions, although other explanations are possible. Patients and surgeons might be less willing to accept re-excisions following OPS because of the primary focus on the cosmetic result. Unfortunately, tumour margin data for the primary procedure are incomplete in the DBCG database for the early years of the present study and could therefore not be included.

Future studies should evaluate whether the effect of OPS on re-excision is similar in patients treated with and without neoadjuvant therapy, as patients who are considered candidates for neoadjuvant therapy, such as those with locally advanced tumours<sup>58</sup>, are also candidates for OPS<sup>16</sup>. Neoadjuvant chemotherapy can be used for tumour downstaging, making more patients eligible for BCS without OPS. It could therefore be argued that there might be less need for OPS in the future as use of neoadjuvant chemotherapy in most high-income countries has been increasing in recent years<sup>8,57</sup>. Neoadjuvant chemotherapy has only been used for breast cancer downstaging in Denmark more recently<sup>59,60</sup>, and patients receiving such treatment were not included in the present study. The increasing use of neoadjuvant chemotherapy might, however, explain the slight decrease in OPS in more recent years in this study.

That changing paradigm from primary BCS to more mastectomy seen in, for instance, the USA could also have

influenced the present findings<sup>61</sup>. Earlier reports from the DBCG database, however, showed that the proportion of patients undergoing primary mastectomy remained stable at around 25 per cent in Denmark during the inclusion period of the present study<sup>59,60</sup>.

This study has several limitations. Several factors, such as breast size<sup>22</sup>, smoking status<sup>11</sup> and surgeons' preference<sup>62</sup>, are known to affect both the choice of surgery and outcomes. Likewise, local resources (such as operating times) and level of experience among staff members can affect both the use of OPS and re-excision rates. Unfortunately, information on these potential confounders was not available. Moreover, the rationale behind the choice of a specific surgical technique (such as racket mammoplasty or reduction with superior pedicle flap) is not registered by the DBCG. Residual confounding by indication could have been present as the matched analyses could only include available variables.

The present findings do not support the use of OPS in all patients undergoing BCS, but rather highlight the safety of OPS for those in whom a satisfactory cosmetic result could not be achieved with BCS alone. This study does not encourage the use of OPS in every patient, but emphasizes its appropriate use in selected patients who otherwise would not be eligible for breast conservation.

## Acknowledgements

Study data can be made available upon reasonable request to the Scientific Committee of Surgery within the DBCG, and the Danish Clinical Registries. This study was supported by funding from the Stichting Professor Michaël-van Vloten Foundation, Nijbakker-Morra Foundation and the Leids University Foundation/Van Trigt Foundation.

*Disclosure:* The authors declare no conflict of interest.

## References

- 1 Blichert-Toft M, Nielsen M, Düring M, Møller S, Rank F, Overgaard M *et al.* Long-term results of breast conserving surgery *vs.* mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol. *Acta Oncol* 2008; **47**: 672–681.
- 2 Litière S, Werutsky G, Fentiman IS, Rutgers E, Christiaens MR, Van Limbergen E *et al.* Breast conserving therapy *versus* mastectomy for stage I–II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. *Lancet Oncol* 2012; **13**: 412–419.
- 3 Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A *et al.* Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical

- mastectomy for early breast cancer. *N Engl J Med* 2002; **347**: 1227–1232.
- 4 Fisher B, Bauer M, Margolese R, Poisson R, Pilch Y, Redmond C *et al*. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. *N Engl J Med* 1985; **312**: 665–673.
  - 5 Veronesi U, Saccozzi R, Del Vecchio M, Banfi A, Clemente C, De Lena M *et al*. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. *N Engl J Med* 1981; **305**: 6–11.
  - 6 Jensen MB, Ejlersen B, Mouridsen HT, Christiansen P; Danish Breast Cancer Cooperative Group. Improvements in breast cancer survival between 1995 and 2012 in Denmark: the importance of earlier diagnosis and adjuvant treatment. *Acta Oncol* 2016; **55**(Suppl 2): 24–35.
  - 7 Integraal Kankercentrum Nedlerland (IKNL). *Cijfers over kanker, overleving borstkanker 2017*; 2017. [https://www.cijfersoverkanker.nl/selecties/overleving\\_borst/img5acb2df1b4cee](https://www.cijfersoverkanker.nl/selecties/overleving_borst/img5acb2df1b4cee) [accessed 1 December 2019].
  - 8 van Bommel A, Spronk P, Mureau M, Siesling S, Smorenburg C, Tollenaar R *et al*. Breast-contour-preserving procedure as a multidisciplinary parameter of esthetic outcome in breast cancer treatment in The Netherlands. *Ann Surg Oncol* 2019; **26**: 1704–1711.
  - 9 Clough KB, Benyahi D, Nos C, Charles C, Sarfati I. Oncoplastic surgery: pushing the limits of breast-conserving surgery. *Breast J* 2015; **21**: 140–146.
  - 10 Jonczyk MM, Jean J, Graham R, Chatterjee A. Surgical trends in breast cancer: a rise in novel operative treatment options over a 12 year analysis. *Breast Cancer Res Treat* 2019; **173**: 267–274.
  - 11 Palsdottir EP, Lund SHL, Asgeirsson KSA. Oncoplastic breast-conserving surgery in Iceland: a population-based study. *Scand J Surg* 2018; **107**: 224–229.
  - 12 Morrow ES, Stallard S, Doughty J, Malyon A, Barber M, Dixon JM *et al*. Oncoplastic breast conservation occupies a niche between standard breast conservation and mastectomy – a population-based prospective audit in Scotland. *Eur J Surg Oncol* 2019; **45**: 1806–1811.
  - 13 Niinikoski L, Leidenius MHK, Vaara P, Voynov A, Heikkilä P, Mattson J *et al*. Resection margins and local recurrences in breast cancer: comparison between conventional and oncoplastic breast conserving surgery. *Eur J Surg Oncol* 2019; **45**: 976–982.
  - 14 Isaacs AJ, Gemignani ML, Pusic A, Sedrakyan A. Association of breast conservation surgery for cancer with 90-day reoperation rates in New York state. *JAMA Surg* 2016; **151**: 648–655.
  - 15 Clough KB, van la Parra RFD, Thygesen HH, Levy E, Russ E, Halabi NM *et al*. Long-term results after oncoplastic surgery for breast cancer: a 10-year follow-up. *Ann Surg* 2018; **268**: 165–171.
  - 16 Clough KB, Kaufman GJ, Nos C, Buccimazza I, Sarfati IM. Improving breast cancer surgery: a classification and quadrant per quadrant atlas for oncoplastic surgery. *Ann Surg Oncol* 2010; **17**: 1375–1391.
  - 17 Losken A, Dugal CS, Styblo TM, Carlson GW. A meta-analysis comparing breast conservation therapy alone to the oncoplastic technique. *Ann Plast Surg* 2014; **72**: 145–149.
  - 18 De La Cruz L, Blankenship SA, Chatterjee A, Geha R, Nocera N, Czerniecki BJ *et al*. Outcomes after oncoplastic breast-conserving surgery in breast cancer patients: a systematic literature review. *Ann Surg Oncol* 2016; **23**: 3247–3258.
  - 19 Chen JY, Huang YJ, Zhang LL, Yang CQ, Wang K. Comparison of oncoplastic breast-conserving surgery and breast-conserving surgery alone: a meta-analysis. *J Breast Cancer* 2018; **21**: 321–329.
  - 20 Santos G, Urban C, Edelweiss MI, Zucca-Matthes G, de Oliveira VM, Arana GH *et al*. Long-term comparison of aesthetical outcomes after oncoplastic surgery and lumpectomy in breast cancer patients. *Ann Surg Oncol* 2015; **22**: 2500–2508.
  - 21 Kelsall JE, McCulley SJ, Brock L, Akerlund MTE, Macmillan RD. Comparing oncoplastic breast conserving surgery with mastectomy and immediate breast reconstruction: case-matched patient reported outcomes. *J Plast Reconstr Aesthet Surg* 2017; **70**: 1377–1385.
  - 22 Kelemen P, Pukancsik D, Újhelyi M, Sávolt Á, Kovács E, Ivády G *et al*. Comparison of clinicopathologic, cosmetic and quality of life outcomes in 700 oncoplastic and conventional breast-conserving surgery cases: a single-centre retrospective study. *Eur J Surg Oncol* 2019; **45**: 118–124.
  - 23 Bodilsen A, Bjerre K, Offersen BV, Vahl P, Ejlersen B, Overgaard J *et al*. The influence of repeat surgery and residual disease on recurrence after breast-conserving surgery: a Danish Breast Cancer Cooperative Group Study. *Ann Surg Oncol* 2015; **22**(Suppl 3): S476–S485.
  - 24 Jeevan R, Cromwell DA, Trivella M, Lawrence G, Kearins O, Pereira J *et al*. Reoperation rates after breast conserving surgery for breast cancer among women in England: retrospective study of Hospital Episode Statistics. *BMJ* 2012; **345**: e4505.
  - 25 Dutch Institute for Clinical Auditing (DICA). *Jaarrapportage 2017*; 2018. <http://dica.nl/jaarrapportage-2017> [accessed 1 December 2019].
  - 26 Wanis ML, Wong JA, Rodriguez S, Wong JM, Jabo B, Ashok A *et al*. Rate of re-excision after breast-conserving surgery for invasive lobular carcinoma. *Ann Surg* 2013; **79**: 1119–1122.
  - 27 Grant Y, Al-Khudairi R, St John E, Barschke M, Cunningham D, Al-Mufti R *et al*. Patient-level costs in margin re-excision for breast-conserving surgery. *Br J Surg* 2019; **106**: 384–394.
  - 28 Dahlbäck C, Manjer J, Rehn M, Ringberg A. Determinants for patient satisfaction regarding aesthetic outcome and skin sensitivity after breast-conserving surgery. *World J Surg Oncol* 2016; **14**: 303.

- 29 Klit A, Tvedskov TF, Kroman N, Elberg JJ, Ejlersen B, Henriksen TF. Oncoplastic breast surgery does not delay the onset of adjuvant chemotherapy: a population-based study. *Acta Oncol* 2017; **56**: 719–723.
- 30 Jensen MB, Laenkholm AV, Offersen BV, Christiansen P, Kroman N, Mouridsen HT *et al.* The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007–2016. *Acta Oncol* 2018; **57**: 13–18.
- 31 Danish Breast Cancer Cooperative Group (DBCG). *DBCG retningslinjer 2011*; 2012. [http://dbcg.dk/PDF%20Filer/Kap\\_4\\_Kirurgisk\\_behandling\\_03.04.13.pdf](http://dbcg.dk/PDF%20Filer/Kap_4_Kirurgisk_behandling_03.04.13.pdf) [accessed 1 December 2019].
- 32 Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. *Clin Epidemiol* 2015; **7**: 449–490.
- 33 Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987; **40**: 373–383.
- 34 Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. *Histopathology* 1991; **19**: 403–410.
- 35 Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH *et al.*; American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *J Clin Oncol* 2013; **31**: 3997–4013.
- 36 Edge S, Byrd DR, Compton CC, Fritz AG, Greene F, Trotti A. *AJCC Cancer Staging Handbook* (7th edn), vol. XIX. Springer: New York, 2010.
- 37 Danish Breast Cancer Cooperative Group (DBCG). *Retningslinier Postoperativ strålebehandling 2016*; 2016; <http://dbcg.dk/PDF%20Filer/Kap%205%20Postoperativ%20strålebehandling%20-%202022.06.2016.pdf> [accessed 1 December 2019].
- 38 Bodilsen A, Bjerre K, Offersen BV, Vahl P, Amby N, Dixon JM *et al.* Importance of margin width in breast-conserving treatment of early breast cancer. *J Surg Oncol* 2016; **113**: 609–615.
- 39 Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. *Multivariate Behav Res* 2011; **46**: 399–424.
- 40 Groenwold RH. [Propensity scores in observational research.] *Ned Tijdschr Geneesk* 2013; **157**: A6179.
- 41 Austin PC. Comparing paired *vs* non-paired statistical methods of analyses when making inferences about absolute risk reductions in propensity-score matched samples. *Stat Med* 2011; **30**: 1292–1301.
- 42 Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. *Stat Med* 2009; **28**: 3083–3107.
- 43 Mansell J, Weiler-Mithoff E, Stallard S, Doughty JC, Mallon E, Romics L. Oncoplastic breast conservation surgery is oncologically safe when compared to wide local excision and mastectomy. *Breast* 2017; **32**: 179–185.
- 44 Mazouni C, Naveau A, Kane A, Dunant A, Garbay JR, Leymarie N *et al.* The role of oncoplastic breast surgery in the management of breast cancer treated with primary chemotherapy. *Breast* 2013; **22**: 1189–1193.
- 45 Borm KJ, Schönknecht C, Nestler A, Oechsner M, Waschulzik B, Combs SE *et al.* Outcomes of immediate oncoplastic surgery and adjuvant radiotherapy in breast cancer patients. *BMC Cancer* 2019; **19**: 907.
- 46 Chakravorty A, Shrestha AK, Sanmugalingam N, Rapisarda F, Roche N, Querci Della Rovere G *et al.* How safe is oncoplastic breast conservation? Comparative analysis with standard breast conserving surgery. *Eur J Surg Oncol* 2012; **38**: 395–398.
- 47 Carter SA, Lyons GR, Kuerer HM, Bassett RL Jr, Oates S, Thompson A *et al.* Operative and oncologic outcomes in 9861 patients with operable breast cancer: single-institution analysis of breast conservation with oncoplastic reconstruction. *Ann Surg Oncol* 2016; **23**: 3190–3198.
- 48 Mukhtar RA, Wong J, Piper M, Zhu Z, Fahrner-Scott K, Mamounas M *et al.* Breast conservation and negative margins in invasive lobular carcinoma: the impact of oncoplastic surgery and shave margins in 358 patients. *Ann Surg Oncol* 2018; **25**: 3165–3170.
- 49 Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J *et al.*; European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. *Lancet Oncol* 2015; **16**: 47–56.
- 50 Grantzau T, Overgaard J. Risk of second non-breast cancer after radiotherapy for breast cancer: a systematic review and meta-analysis of 762 468 patients. *Radiother Oncol* 2015; **114**: 56–65.
- 51 Taylor CW, Nisbet A, McGale P, Darby SC. Cardiac exposures in breast cancer radiotherapy: 1950s–1990s. *Int J Radiat Oncol Biol Phys* 2007; **69**: 1484–1495.
- 52 Offersen BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Biete Sola A *et al.* ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. *Radiother Oncol* 2015; **114**: 3–10.
- 53 Clough KB, Gouveia PF, Benyahi D, Massey EJ, Russ E, Sarfati I *et al.* Positive margins after oncoplastic surgery for breast cancer. *Ann Surg Oncol* 2015; **22**: 4247–4253.
- 54 De Lorenzi F, Hubner G, Rotmensz N, Bagnardi V, Loschi P, Maisonneuve P *et al.* Oncological results of oncoplastic breast-conserving surgery: long term follow-up of a large series at a single institution: a matched-cohort analysis. *Eur J Surg Oncol* 2016; **42**: 71–77.

- 55 Semprini G, Cattin F, Vaienti L, Brizzolari M, Cedolini C, Parodi PC. Oncoplastic surgery and cancer relapses: cosmetic and oncological results in 489 patients. *Breast* 2013; **22**: 946–951.
- 56 Langhans L, Jensen MB, Talman MM, Vejborg I, Kroman N, Tvedskov TF. Reoperation rates in ductal carcinoma *in situ* vs invasive breast cancer after wire-guided breast-conserving surgery. *JAMA Surg* 2017; **152**: 378–384.
- 57 Rezai M, Knispel S, Kellersmann S, Lax H, Kimmig R, Kern P. Systematization of oncoplastic surgery: selection of surgical techniques and patient-reported outcome in a cohort of 1035 patients. *Ann Surg Oncol* 2015; **22**: 3730–3737.
- 58 Holmes D, Colfry A, Czerniecki B, Dickson-Witmer D, Francisco Espinel C, Feldman E *et al*. Performance and practice guideline for the use of neoadjuvant systemic therapy in the management of breast cancer. *Ann Surg Oncol* 2015; **22**: 3184–3190.
- 59 Danish Breast Cancer Cooperative Group (DBCG). *Kvalitetsindikatorrapport for Brystkræft 2017*; DBCG: Copenhagen, 2018.
- 60 Danish Breast Cancer Cooperative Group (DBCG). *Kvalitetsindikatorrapport for Brystkræft 2015*. DBCG: Copenhagen, 2016.
- 61 Lucas DJ, Sabino J, Shriver CD, Pawlik TM, Singh DP, Vertrees AE. Doing more: trends in breast cancer surgery, 2005 to 2011. *Am Surg* 2015; **81**: 74–80.
- 62 Carstensen L, Rose M, Bentzon N, Kroman NT. Knowledge and opinions on oncoplastic surgery among breast and plastic surgeons. *Dan Med J* 2015; **62**: A5030.

### Supporting information

Additional supporting information can be found online in the Supporting Information section at the end of the article.